All of the women had breast-conserving surgery, and 71% of them had radiation therapy.[24]No difference in the rate of breast cancer recurrence in favor of anastrozole was found (HR, 0.89; 95% CI, 0.64–1.23;P= .49), and there was no difference in survival.
No difference in the rate of breast cancer recurrence in favor of anastrozole was found (HR, 0.89; 95% CI, 0.64–1.23;P= .49), and there was no difference in survival.
The decision to prescribe endocrine therapy after a diagnosis of DCIS often involves a discussion with the patient about the potential benefits and side effects of each agent.
Use ouradvanced clinical trial searchto find NCI-supported cancer clinical trials that are now enrolling patients.